Advertisement

Refining age stratum of the C2HEST score for predicting incident atrial fibrillation in a hospital-based Chinese population

      Highlights

      • Incident atrial fibrillation is prevalent in hospital-based Chinese population.
      • The mC2HEST score had better predictive and discriminative ability for incident AF.
      • The mC2HEST score also showed moderate predictive capability for ischemic stroke.

      Abstract

      Background

      The C2HEST score (C2: coronary artery disease [CAD] / chronic obstructive pulmonary disease [COPD] (1 point each); H: Hypertension; E: Elderly (Age≥75, doubled); S: Systolic heart failure (doubled); T: Thyroid disease (hyperthyroidism)) has been validated to predict incident atrial fibrillation (AF). Its performance in the hospital-based Chinese population has never been evaluated.

      Methods

      Risk factors for incident AF were investigated in a hospital-based population. Comparison of the C2HEST score and other clinical scores with the capacity of predicting incident AF was conducted using area under the curves (AUC), net reclassification index (NRI), integrated discriminative improvement (IDI), and decision curve analysis (DCA). An age-stratified criterion was used to refine the C2HEST score to form a modified C2HEST score (mC2HEST). The performance of the mC2HEST score was also evaluated.

      Results

      A total of 23,523 patients entered the study with 520 developed AF during 2.84 ± 3.56 years of follow-up. Risk factors for incident AF included age, male sex, hypertension, CAD, COPD, previous ischemic stroke, hyperthyroidism, and heart failure. Age ≥65 years has significantly increased the risk of AF, which was considered as the age cutoff for a modified C2HEST score (mC2HEST). The risk of AF increased by 89% per one-point increase of the mC2HEST score. The mC2HEST score showed better predictive performance (AUC of 0.809) compared with the original C2HEST (AUC of 0.752), CHA2DS2-VASc (0.756), HATCH (0.722), and HAVOC (0.758) scores, also as estimated by IDI, NRI and DCA. Among those enrolled after 2012, the mC2HEST score had numerically higher AUC (0.849) compared with the C2HEST score (0.826) and the other scores.

      Conclusion

      In a hospital-based Chinese population, by refining the age strata of the original C2HEST score, the mC2HEST score had significantly increased predictive accuracy and discriminative capability for incident AF. The clinical benefits of the application of novel mC2HEST score needs further validation in multiple settings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Reference

        • Wolf PA
        • Abbott RD
        • Kannel WB.
        Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
        Stroke. 1991; 22: 983-988
        • Miyasaka Y
        • Barnes ME
        • Gersh BJ
        • Cha SS
        • Bailey KR
        • Abhayaratna W
        • et al.
        Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades.
        Eur Heart J. 2006; 27: 936-941https://doi.org/10.1093/eurheartj/ehi694
        • Piccini JP
        • Hammill BG
        • Sinner MF
        • Jensen PN
        • Hernandez AF
        • Heckbert SR
        • et al.
        Incidence and prevalence of atrial fibrillation and associated mortality among medicare beneficiaries, 1993-2007.
        Circ Cardiovasc Qual Outcomes. 2012; 5: 85-93https://doi.org/10.1161/CIRCOUTCOMES.111.962688
        • Benjamin EJ
        • Wolf PA
        • D'Agostino RB
        • Silbershatz H
        • Kannel WB
        • Levy D
        Impact of atrial fibrillation on the risk of death: the Framingham heart study.
        Circulation. 1998; 98: 946-952
        • Hindricks G
        • Potpara T
        • Dagres N
        • Arbelo E
        • Bax JJ
        • Blomstrom-Lundqvist C
        • et al.
        2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of cardio-thoracic surgery (EACTS).
        Eur Heart J. 2020; pii5899003https://doi.org/10.1093/eurheartj/ehaa612
        • Li YG
        • Pastori D
        • Farcomeni A
        • Yang PS
        • Jang E
        • Joung B
        • et al.
        A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects..
        Chest. 2019; 155: 510-518https://doi.org/10.1016/j.chest.2018.09.011
        • Hu WS
        • Lin CL.
        Prediction of new-onset atrial fibrillation for general population in Asia: a comparison of C2HEST and HATCH scores.
        Int. J. Cardiol. 2020; 313: 60-63https://doi.org/10.1016/j.ijcard.2020.03.036
        • Li YG
        • Bisson A
        • Bodin A
        • Herbert J
        • Grammatico-Guillon L
        • Joung B
        • et al.
        C2HEST Score and prediction of incident atrial fibrillation in poststroke patients: a French nationwide study.
        J. Am. Heart Assoc. 2019; 8e012546https://doi.org/10.1161/JAHA.119.012546
        • Lip GYH
        • Skjoth F
        • Nielsen PB
        • Larsen TB.
        Evaluation of the C2HEST risk score as a possible opportunistic screening tool for incident atrial fibrillation in a healthy population (from a nationwide danish cohort study).
        Am. J. Cardiol. 2019; 125: 48-54https://doi.org/10.1016/j.amjcard.2019.09.034
        • Hu WS
        • Lin CL.
        Comparison of CHA2DS2-VASc and C2HEST scores for predicting the incidence of atrial fibrillation among patients with end-stage renal disease..
        Perfusion. 2020; 35: 842-846https://doi.org/10.1177/0267659120930931
        • Lip GYH
        • Skjoth F
        • Nielsen PB
        • Larsen TB.
        Evaluation of the C2HEST risk score as a possible opportunistic screening tool for incident atrial fibrillation in a healthy population (from a nationwide danish cohort study).
        Am. J. Cardiol. 2020; 125: 48-54https://doi.org/10.1016/j.amjcard.2019.09.034
        • Liang W
        • Wu Y
        • Xue R
        • Wu Z
        • Wu D
        • He J
        • et al.
        C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial.
        BMC Med. 2021; 19: 44https://doi.org/10.1186/s12916-021-01921-w
        • Li YG
        • Pastori D
        • Miyazawa K
        • Shahid F
        • Lip GYH.
        Identifying at-risk patients for sustained atrial high-rate episodes using the C2HEST score: the west Birmingham atrial fibrillation project.
        J. Am. Heart Assoc. 2021; 10 (e)017519https://doi.org/10.1161/JAHA.120.017519
        • Guo Y
        • Wang H
        • Zhang H
        • Chen Y
        • Lip GYH.
        Population-based screening or targeted screening based on initial clinical risk assessment for atrial fibrillation: a report from the Huawei heart study.
        J. Clin. Med. 2020; 9https://doi.org/10.3390/jcm9051493
        • Lip GY
        • Nieuwlaat R
        • Pisters R
        • Lane DA
        • Crijns HJ.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272https://doi.org/10.1378/chest.09-1584
        • Suenari K
        • Chao TF
        • Liu CJ
        • Kihara Y
        • Chen TJ
        • Chen SA.
        Usefulness of HATCH score in the prediction of new-onset atrial fibrillation for Asians.
        Medicine. 2017; 96: e5597https://doi.org/10.1097/MD.0000000000005597
        • Pencina MJ
        • D'Agostino RB
        • D'Agostino RB
        • Vasan RS
        Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.
        Stat. Med. 2008; 27 (Sr.Jr.) (discussion 207-12): 157-172https://doi.org/10.1002/sim.2929
        • Vickers AJ
        • Cronin AM
        • Elkin EB
        • Gonen M.
        Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers.
        BMC Med. Inform. Decis. Mak. 2008; 8: 53https://doi.org/10.1186/1472-6947-8-53
        • Vickers AJ
        • Elkin EB.
        Decision curve analysis: a novel method for evaluating prediction models.
        Med. Decis. Making. 2006; 26 (10.1177/0272989×06295361): 565-574
        • Andrade J
        • Khairy P
        • Dobrev D
        • Nattel S.
        The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.
        Circ. Res. 2014; 114: 1453-1468https://doi.org/10.1161/CIRCRESAHA.114.303211
        • Benjamin EJ
        • Go AS
        • Desvigne-Nickens P
        • Anderson CD
        • Casadei B
        • Chen LY
        • et al.
        Research priorities in atrial fibrillation screening: a report from a national heart, lung, and blood institute virtual workshop.
        Circulation. 2021; 143: 372-388https://doi.org/10.1161/CIRCULATIONAHA.120.047633
        • January CT
        • Wann LS
        • Calkins H
        • Chen LY
        • Cigarroa JE
        • Cleveland JC
        • et al.
        2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons.
        Circulation. 2019; 140: e125-ee51https://doi.org/10.1161/CIR.0000000000000665
        • Jacobs MS
        • Kaasenbrood F
        • Postma MJ
        • van Hulst M
        • Tieleman RG.
        Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands.
        Europace. 2018; 20: 12-18https://doi.org/10.1093/europace/euw285
        • Vermond RA
        • Geelhoed B
        • Verweij N
        • Tieleman RG
        • Van der Harst P
        • Hillege HL
        • et al.
        Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands.
        Journal of the American College of Cardiology. 2015; 66: 1000-1007https://doi.org/10.1016/j.jacc.2015.06.1314
        • Guo Y
        • Tian Y
        • Wang H
        • Si Q
        • Wang Y
        • Lip GYH.
        Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation.
        Chest. 2015; 147: 109-119https://doi.org/10.1378/chest.14-0321
        • Schnabel RB
        • Haeusler KG
        • Healey JS
        • Freedman B
        • Boriani G
        • Brachmann J
        • et al.
        Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN international collaboration.
        Circulation. 2019; 140: 1834-1850https://doi.org/10.1161/CIRCULATIONAHA.119.040267
        • Camelo-Castillo A
        • Rivera-Caravaca JM
        • Marin F
        • Vicente V
        • Lip GYH
        • Roldan V.
        Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: the murcia AF project.
        Thromb Haemost. 2020; 120: 1200-1207https://doi.org/10.1055/s-0040-1712914
        • Esteve-Pastor MA
        • Roldan V
        • Rivera-Caravaca JM
        • Ramirez-Macias I
        • Lip GYH
        • Marin F.
        The use of biomarkers in clinical management guidelines: a critical appraisal.
        Thromb. Haemost. 2019; 119: 1901-1919https://doi.org/10.1055/s-0039-1696955
        • Proietti M
        • Rivera-Caravaca JM
        • Esteve-Pastor MA
        • Marin F
        • Lip GYH.
        Stroke and thromboembolism in warfarin-treated patients with atrial fibrillation: comparing the CHA2DS2-VASc and GARFIELD-AF risk scores.
        Thromb. Haemost. 2020; https://doi.org/10.1055/a-1333-4448